• 1
    Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. [see comment]. J Natl Cancer Inst 1995; 87: 796802.
  • 2
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 1219.
  • 3
    Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi FE, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V. A review of human carcinogens-Part B: biological agents. Lancet Oncol 2009; 10: 3212.
  • 4
    Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 1015.
  • 5
    Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121: 62132.
  • 6
    Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 175765.
  • 7
    Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 2718.
  • 8
    Liaw KL, Hsing AW, Chen CJ, Schiffman MH, Zhang TY, Hsieh CY, Greer CE, You SL, Huang TW, Wu TC, et al. Human papillomavirus and cervical neoplasia: a case-control study in Taiwan. Int J Cancer 1995; 62: 56571.
  • 9
    Liaw KL, Hsing AW, Schiffman MH, You SL, Zhang T, Burk R, Chen CJ. Human papillomavirus types 52 and 58 are prevalent in cervical cancer from Chinese women.[comment]. Int J Cancer 1997; 73: 7756.
  • 10
    Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 6373.
  • 11
    de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7: 4539.
  • 12
    Sasagawa T, Tani M, Yasuda H, Khadijeh KA, Sakai A, Fukae T, Ukita T, Yamazaki H, Satake S, Nakano T, Inoue M. Sexual behaviour and high risk human papillomavirus infections in Japanese women. Sexually Trans Inf 2005; 81: 2802.
  • 13
    Chan PK, Mak KH, Cheung JL, Tang NL, Chan DP, Lo KK, Cheng AF. Genotype spectrum of cervical human papillomavirus infection among sexually transmitted disease clinic patients in Hong Kong. J Med Virol 2002; 68: 2737.
  • 14
    Jeng CJ, Phdl, Ko ML, Ling QD, Shen J, Lin HW, Tzeng CR, Ho CM, Chien TY, Chen SC. Prevalence of cervical human papillomavirus in Taiwanese women. Clin Invest Med 2005; 28: 2616.
  • 15
    Lin H, Ma YY, Moh JS, Ou YC, Shen SY, ChangChien CC. High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan. Gynecol Oncol 2006; 101: 405.
  • 16
    Huang YK, You SL, Yuan CC, Ke YM, Cao JM, Liao CY, Wu CH, Hsu CS, Huang KF, Lu CH, Twu NF, Chu TY. Long-term outcomes of high-risk human papillomavirus infection support a long interval of cervical cancer screening. Br J Cancer 2008; 98: 8639.
  • 17
    Chao A, Hsu KH, Lai CH, Huang HJ, Hsueh S, Lin SR, Jung SM, Chao FY, Huang SL, Huang CC, Yang JE, Chang TC. Cervical cancer screening program integrating Pap smear and HPV DNA testing: a population-based study. Int J Cancer 2008; 122: 283541.
  • 18
    Bao YP, Li N, Smith JS, Qiao YL. Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis. Int J STD AIDS 2008; 19: 10611.
  • 19
    Lin CY, Chen HC, Lin RW, You SL, You CM, Chuang LC, Pan MH, Lee MH, Chou YC, Chen CJ. Quality assurance of genotyping array for detection and typing of human papillomavirus. J Virol Methods 2007; 140: 19.
  • 20
    Huang HJ, Huang SL, Lin CY, Lin RW, Chao FY, Chen MY, Chang TC, Hsueh S, Hsu KH, Lai CH. Human papillomavirus genotyping by a polymerase chain reaction-based genechip method in cervical carcinoma treated with neoadjuvant chemotherapy plus radical surgery. Int J Gynecol Cancer 2004; 14: 63949.
  • 21
    Lin CY, Chao A, Yang YC, Chou HH, Ho CM, Lin RW, Chang TC, Chiou JY, Chao FY, Wang KL, Chien TY, Hsueh S, et al. Human papillomavirus typing with a polymerase chain reaction-based genotyping array compared with type-specific PCR. J Clin Virol 2008; 42: 3617.
  • 22
    Liaw KL, Glass AG, Manos MM, Greer CE, Scott DR, Sherman M, Burk RD, Kurman RJ, Wacholder S, Rush BB, Cadell DM, Lawler P, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 1999; 91: 95460.
  • 23
    Schiffman M, Clifford G, Buonaguro F. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Inf Agents Cancer 2009; 4: 8.
  • 24
    Broder S. Rapid communication—The Bethesda system for reporting cervical/vaginal cytologic diagnoses—Report of the 1991 Bethesda Workshop. JAMA 1992; 267: 1892.
  • 25
    Silverman DT, Brown LM, Hoover RN, Schiffman M, Lillemoe KD, Schoenberg JB, Swanson GM, Hayes RB, Greenberg RS, Benichou J, et al. Alcohol and pancreatic cancer in blacks and whites in the United States. Cancer Res 1995; 55: 4899905.
  • 26
    Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366: 9918.
  • 27
    Bao YP, Li N, Smith JS, Qiao YL. Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer 2008; 18: 719.
  • 28
    Porras C, Rodríguez AC, Hildesheim A, Herrero R, González P, Wacholder S, Burk RD, Schiffman M. Human papillomavirus types by age in cervical cancer precursors: predominance of human papillomavirus 16 in young women. Cancer Epidemiol Biomarkers Prev 2009; 18: 8635.
  • 29
    Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357: 18316.
  • 30
    Kovacic MB, Castle PE, Herrero R, Schiffman M, Sherman ME, Wacholder S, Rodriguez AC, Hutchinson ML, Bratti MC, Hildesheim A, Morales J, Alfaro M, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 2006; 66: 101129.
  • 31
    Van Ranst M, Kaplan JB, Burk RD. Phylogenetic classification of human papillomaviruses: correlation with clinical manifestations. J General Virol 1992; 73: 265360.
  • 32
    Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study G. Epidemiologic classification of human papillomavirus types associated with cervical cancer.[see comment]. New Engl J Med 2003; 348: 51827.
  • 33
    Chen YY, You SL, Chen CA, Shih LY, Koong SL, Chao KY, Hsiao ML, Hsieh CY, Chen CJ. Effectiveness of national cervical cancer screening programme in Taiwan: 12-year experiences. Br J Cancer 2009; 101: 1747.
  • 34
    Tay SK, Ngan HY, Chu TY, Cheung AN, Tay EH. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan. Vaccine 2008; 26 Suppl 12: M60M70.
  • 35
    Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 27885.
  • 36
    Schiffman M, Rodriguez AC, Chen Z, Wacholder S, Herrero R, Hildesheim A, Desalle R, Befano B, Yu K, Safaeian M, Sherman ME, Morales J, et al. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res 70: 315969.
  • 37
    Chan PK, Lam CW, Cheung TH, Li WW, Lo KW, Chan MY, Cheung JL, Cheng AF. Association of human papillomavirus type 58 variant with the risk of cervical cancer. J Natl Cancer Inst 2002; 94: 124953.
  • 38
    Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow S-N, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 216170.
  • 39
    Brown DR, Kjaer SK, Sigurdsson K, Iversen Or, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to ncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Inf Dis 2009; 199: 92635.
  • 40
    Herrero R. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Inf Dis 2009; 199: 91922.
  • 41
    Wheeler CM, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J Inf Dis 2009; 199: 93644.
  • 42
    Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Munoz N. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26: K1K16.